ClinicalTrials.gg
CompletedNCT01970865Updated Aug 12, 2024Results posted

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

A Phase 1/2 interventional study of PF-06463922 and Crizotinib in ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, sponsored by Pfizer. Completed at 77 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
364
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 27
364 · median 45
Started
2014
the only one that year
Phase 1/2
3 of 27
none open now
Registered
1st of 27
by date
Lead sponsor
8 of 27
Pfizer

Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is the only one that started in 2014, is one of 3 in phase 1/2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About lorlatinib

lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

03

Conditions studied

  • ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

Keywords

  • Phase 1
  • Phase 2
  • safety
  • pharmacokinetic
  • pharmacodynamic
  • efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Evidence of or cytologically confirmed diagnosis of NSCLC (Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food and Drug Administration (FDA) approved FISH assay (Abbott Molecular Inc) or by Immunohistochemistry (IHC) (Ventana Inc), or a ROS1 rearrangement as determined by FISH or RT PCR or Next Generation Sequencing (NGS) via a local diagnostic test (LDT). All patients (ALK positive and ROS1 positive) must have sample available and collected prior to enrollment.
  • Disease Status Requirements:

Phase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naïve in the advanced setting or have had disease progression after at least 1 previous ALK/ROS1 inhibitor therapy(ies).

Phase 2:

ALK-positive NSCLC patients must either be or have had:

  • Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no prior ALK inhibitor therapy allowed).
  • Disease progression after crizotinib only. No prior chemotherapy is allowed in the metastatic disease setting.
  • Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the metastatic disease setting.
  • Disease progression after 1 prior ALK inhibitor therapy other than crizotinib. Patients may have had any number of prior chemotherapy regimens in any disease setting.
  • Disease progression after 2 prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting.
  • Disease progression after 3 prior ALK inhibitor therapies. Patients may have had any number of prior chemotherapy regimens in any disease setting.

ROS1-positive NSCLC patients may be:

  • Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no prior ROS inhibitor therapy).
  • Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).

    • Tumor Requirements:

All Patients must have at least one measurable target extracranial lesion according to v1.1. In addition patients with asymptomatic (including patients asymptomatic by means of stable or decreasing doses of within the last 2 weeks prior to study entry) will be eligible. Patients who have (LM) or carcinomatous meningitis (CM) are eligible.

  • Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.
  • Negative Serum pregnancy test for females of Exclusion Criteria
  • Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.
  • Systemic anti cancer therapy completed within a minimum of 5 half lives of study entry.
  • Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including, but not limited to, , anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (anti-CTLA-4) antibody.
  • Active and bacterial, fungal, or viral infection including (HBV), (HCV), known (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
  • Clinically significant cardiovascular disease (that is, active or \<3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure ( Classification Class ≥ II), second-degree or third-degree AV block (unless paced) or any AV block with PR >220 msec. Ongoing cardiac dysrhythmias of Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read with >470 msec, or congenital long QT syndrome.
  • History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.
  • Current use or anticipated need for food or drugs that are known strong or moderate inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are sensitive CYP2B6 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
364 participants (actual)

Study arms

  • Experimental
    PF-06463922

    Drug: PF-06463922

  • Other
    Crizotinib

    ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.

    Drug: Crizotinib

Interventions

  • Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days

  • Oral, starting dose of 250 mg BID continuous daily dosing every 21 days

    Also known as: Xalkori

06

What researchers measure

Primary outcomes

  1. Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1

    DLT: any of following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for \>7 days; febrile neutropenia; grade\>=3 neutropenic infection; grade\>=3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade\>=3 pancreatitis; grade\>=3 toxicities (excluding grade \>=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade \>=3 QT interval corrected for heart rate (QTc) prolongation, or asymptomatic grade \>=3 prolongation that had been confirmed by repeat testing, re-evaluation by qualified person, persisted after correction of reversible causes; \>=20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of 21 prescribed daily total dose due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicity attributable to study drug.

    Time frame: Cycle 1 (21 days)

  2. Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)

    Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions electronic case report form (eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

    Time frame: 3 years

Secondary outcomes

  1. Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)

    Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

    Time frame: From start of study treatment until CR or PR (maximum of 8 years approximately)

  2. Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)

    Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.

    Time frame: From start of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 8 years approximately)

  3. Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)

    Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.

    Time frame: From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)

  4. Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)

    Tumor response was evaluated according to RECIST version 1.1, and disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR was defined as disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review.

    Time frame: 12 and 24 weeks

  5. Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)

    The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either "CNS progression" or "non CNS progression" or "Death") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.

    Time frame: 3 years

  6. Progression-Free Survival (PFS) (Phase 1)

    PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.

    Time frame: From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)

  7. Overall Survival (OS) (Phase 1)

    OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.

    Time frame: 3 years

  8. Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)

    Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.

  9. Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).

  10. Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)

    Tmax of PF-06463922 was observed directly from data as time of first occurrence.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.

  11. Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Tmax of PF-06463922 was observed directly from data as time of first occurrence.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).

  12. Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)

    Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups.

  13. Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)

  14. Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)

    AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.

  15. Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.

  16. Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)

  17. Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)

    Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.

  18. Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)

  19. Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)

    Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.

  20. Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)

    Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)

  21. Renal Clearance (CLr) of PF-06463922 (Phase 1)

    Renal clearance was calculated as Aetau/AUCtau, where Aetau was the cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen).

    Time frame: 0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15

  22. Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)

    Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100\*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.

    Time frame: 0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15

  23. Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)

    Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  24. Time for Cmax (Tmax) of Midazolam (Phase 1)

    Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  25. Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)

    Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  26. Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)

    AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  27. Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  28. Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)

    Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  29. Terminal Half-Life of Midazolam (Phase 1)

    Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  30. Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)

    Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.

    Time frame: Screening (up to 28 days)

  31. Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)

    Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.

    Time frame: Screening (up to 28 days)

  32. Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)

    European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

    Time frame: From start of study treatment until end of treatment (maximum of 8 years approximately)

  33. Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)

    EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

    Time frame: From start of study treatment until end of treatment (maximum of 8 years approximately)

  34. Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)

    In Phase 1, the MMSE was collected to assess mental status. The MMSE is a 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30 and minimum score is 0. Highest score indicates no cognitive impairment, lowest score indicates severe cognitive impairment. The MMSE was removed under Amendment 6 of the study protocol, and not required for Phase 2, as the tool was not considered meaningful for assessment of cognitive function.

    Time frame: Baseline, Day 1 of Cycle 1-52, and end of treatment (up to 3 years)

  35. Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI Sub-study)

    Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

    Time frame: From first dose of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  36. Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy)

    Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of PD or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.

    Time frame: From first dose of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  37. Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy)

    Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed CR, confirmed PR, or stable disease (SD). CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. SD= when neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD is observed, taking as reference the smallest sum diameters while on study. Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.

    Time frame: Weeks 12 and 24

  38. Time to Progression on the Last Prior Therapy (Phase 2)

    TTP on the last prior therapy was defined as time from the first dose date of the last prior treatment regimen to the date of progression. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose.

    Time frame: From first dose of study treatment to the date of progression (maximum of 7.5 years for Phase 2)

  39. Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy)

    Time to progression (TTP) was defined as the time from the first dose of study treatment to the first documentation of objective PD. Intracranial TTP was defined as the time from the first dose of study treatment to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.

    Time frame: From first dose of study treatment to the first documentation of objective PD (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  40. Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)

    Probability of first event being CNS progression, non-CNS progression, or death was evaluated with competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to analysis set. Time to first event being Competing Event (either "CNS progression" or "non CNS progression" or "Death") = time from first dose until date of that specific event. Participants not known to have any of Competing Events were censored on date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as competing cause of failure for analysis of other type of events. For each type of event, cumulative incidence function corresponding to nearest time point preceding 1 year is presented. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm(\>=5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.

    Time frame: From first dose of study treatment until first event of CNS progression (maximum of 7.5 years for Phase 2)

  41. Progression-Free Survival (PFS) (Phase 2 and DDI Substudy)

    PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.

    Time frame: From first dose of study treatment to first documentation of objective PD or death due to any cause, whichever came first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  42. Overall Survival (Phase 2 and DDI Substudy)

    OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.

    Time frame: From first dose of study treatment until date of death (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  43. Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)

    Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  44. Time for Cmax (Tmax) of PF-06463922 (Phase 2)

    Tmax of PF-06463922 was observed directly from data as time of first occurrence.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  45. Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)

    AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7

  46. Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)

    Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  47. Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  48. Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)

    Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7

  49. Terminal Half-Life of PF-06463922 (Phase 2)

    Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7

  50. Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)

    Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2).

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  51. Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)

    Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15

  52. Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)

    Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented.

    Time frame: Screening (up to 28 days)

  53. Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)

    Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.

    Time frame: Screening (up to 28 days)

  54. Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study)

    European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

    Time frame: From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  55. Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study)

    EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

    Time frame: From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  56. Number of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study)

    AE: any untoward medical occurrence in clinical investigation participant administered a product or medical device, regardless of causal relationship to study treatment. Treatment-emergent AEs (TEAEs): AEs which occurred for first time during effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs): any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of ability to conduction normal life function). AEs included SAEs and non-serious AEs. Severity was graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Grade1: mild, Grade2: moderate, Grade3: severe, Grade4: Life threatening consequences; urgent intervention indicated, Grade 5: death related to AE.

    Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  57. Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Hematology

    Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Hematology parameters with any abnormalities were reported in this outcome measure.

    Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  58. Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Chemistry

    Chemistry evaluation included alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, creatine phosphokinase (CPK), creatinine, gamma-glutamyl transferase (GGT), calcium, sodium, potassium, magnesium, albumin, glucose (non-fasted), albumin, phosphorus or phosphate, serum amylase and lipase.

    Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  59. Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Coagulation, Lipids and Urinalysis

    Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included Cholesterol and triglycerides.

    Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  60. Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)

    Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured.

    Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  61. Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study)

    Left Ventricular Ejection Fraction (LVEF) was determined by echocardiogram. Baseline was defined as the measurement prior to the first dose of study treatment.

    Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  62. Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)

    Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia's formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment.

    Time frame: From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

  63. Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)

    The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide. Maximum score of 4 or 5 indicates maximum suicidal ideation and minimum score of "0" indicates no suicidal ideation.

    Time frame: From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2)

  64. Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)

    The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.

    Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)

  65. Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)

    The Detection Test is a measure of psychomotor function and uses a well validated simple reaction time paradigm with playing card stimuli. In this test, the on-screen instructions ask: "Has the card turned over?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as the card flips over the participant must press "Yes". The participant is encouraged to work as quickly as they can and be as accurate as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

    Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)

  66. Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)

    The Identification Test is a measure of visual attention and uses a well validated choice reaction time paradigm with playing card stimuli. In this task, the playing cards are all red or black jokers. The on-screen instructions ask: "Is the card red?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as it flips over the participant must decide whether the card is red or not. If it is red the participant should press "Yes", and if it is not red the participant should press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

    Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)

  67. Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)

    The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: "Is the previous card the same?". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press "Yes", and if not press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

    Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)

  68. Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)

    The International Shopping List task is a measure of verbal learning and uses a well validated list learning paradigm administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to the participant at the rate of one word every 2 seconds. Once all 12 words had been read, the participant was asked to recall as many of the words as quickly as possible. The words recalled by the participant were marked on the computer screen. When the participant could recall no more words, the same list was read again. The words recalled by the participant were recorded. This was then repeated a third time. Total number of correct responses on 3 consecutive trials at a single assessment was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

    Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)

  69. Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)

    This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

    Time frame: Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)

  70. Number of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy)

    PR Interval was determined by ECG measurement. PR interval had following categories: change from baseline\>=25 percent, 40 to \<60 milliseconds (msec), 60 to \<80 msec and \>=80 msec. Baseline was defined as the average of the triplicate measurements prior to the first dose of study drug.

    Time frame: From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

Other outcomes

  1. Percentage of Participants With Overall and Intracranial Objective Response (Phase 2 and DDI Sub-study)

    Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

    Time frame: From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)

07

Results

Posted May 29, 2018

Participant flow

Participant flow — Overall Study
Milestone10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)Japan Lead-In Cohort (LIC)Drug-drug Interaction (DDI) Sub-study
Started333121733334302760654647332
Completed00023000121871883726
Not completed333101433322122042574340126
Withdrew: Death323693232281325463722117
Withdrew: Lost to follow-up000110000010201401
Withdrew: Other010110100023832302
Withdrew: Participant refused further follow-up0002300000147831106

Outcome measures

PrimaryNumber of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1

DLT: any of following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for \>7 days; febrile neutropenia; grade\>=3 neutropenic infection; grade\>=3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade\>=3 pancreatitis; grade\>=3 toxicities (excluding grade \>=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade \>=3 QT interval corrected for heart rate (QTc) prolongation, or asymptomatic grade \>=3 prolongation that had been confirmed by repeat testing, re-evaluation by qualified person, persisted after correction of reversible causes; \>=20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of 21 prescribed daily total dose due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicity attributable to study drug.

Time frame:
Cycle 1 (21 days)
Reported as:
Count of participants · Participants
Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
With DLT0000001000
No DLT3236821232
Data missing0105811001
PrimaryPercentage of Participants With Overall and Intracranial Objective Response (Phase 2)

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions electronic case report form (eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

Time frame:
3 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)
Percentage of participantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Objective response90.0 (73.5 to 97.9)74.1 (53.7 to 88.9)50.8 (37.5 to 64.1)41.5 (29.4 to 54.4)34.8 (21.4 to 50.2)36.2 (22.7 to 51.5)
Intracranial objective response75.0 (34.9 to 96.8)58.8 (32.9 to 81.6)62.5 (43.7 to 78.9)55.6 (40.0 to 70.4)39.5 (24.0 to 56.6)56.0 (34.9 to 75.6)
SecondaryPercentage of Participants With Overall and Intracranial Objective Response (Phase 1)

Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

Time frame:
From start of study treatment until CR or PR (maximum of 8 years approximately)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)
Percentage of participantsALK Positive Population (Phase 1)ROS1 Positive Population (Phase 1)
Objective response39.0 (24.2 to 55.5)50.0 (21.1 to 78.9)
Intracranial objective response41.2 (24.6 to 59.3)50.0 (15.7 to 84.3)
SecondaryTime to Tumor Response (TTR) and Intracranial TTR (Phase 1)

Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.

Time frame:
From start of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 8 years approximately)
Reported as:
Median · Months
Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)
MonthsALK Positive Population (Phase 1)ROS1 Positive Population (Phase 1)
TTR1.4 (1.2 to 15.2)1.4 (1.2 to 2.8)
Intracranial TTR1.4 (1.2 to 20.1)1.4 (1.1 to 2.8)
SecondaryNumber of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)

Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of disease progression (PD) or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.

Time frame:
From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)
Reported as:
Count of participants · Participants
Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1)
ParticipantsALK Positive Population (Phase 1)ROS1 Positive Population (Phase 1)
Participants with DOR — <3 Months10
Participants with DOR — 3 Months to <6 Months60
Participants with DOR — 6 Months to <9 Months01
Participants with DOR — 9 Months to <12 Months01
Participants with DOR — 12 Months to <15 Months10
Participants with DOR — 15 Months to <18 Months00
Participants with DOR — 18 Months to <21 Months00
Participants with DOR — 21 Months to <24 Months10
Participants with DOR — >=24 Months12
Participants censored-DOR — <3 Months00
Participants censored-DOR — 3 Months to <6 Months00
Participants censored-DOR — 6 Months to <9 Months00
Participants censored-DOR — 9 Months to <12 Months00
Participants censored-DOR — 12 Months to <15 Months00
Participants censored-DOR — 15 Months to <18 Months00
Participants censored-DOR — 18 Months to <21 Months00
Participants censored-DOR — 21 Months to <24 Months01
Participants censored-DOR — >=24 Months61
Participants with intracranial DOR — <3 Months10
Participants with intracranial DOR — 3 Months to <6 Months00
Participants with intracranial DOR — 6 Months to <9 Months10
Participants with intracranial DOR — 9 Months to <12 Months00
Participants with intracranial DOR — 12 Months to <15 Months10
Participants with intracranial DOR — 15 Months to <18 Months00
Participants with intracranial DOR — 18 Months to <21 Months00
Participants with intracranial DOR — 21 Months to <24 Months00
Participants with intracranial DOR — >=24 Months00
Participants censored- intracranial DOR — <3 Months11
Participants censored- intracranial DOR — 3 Months to <6 Months20
Participants censored- intracranial DOR — 6 Months to <9 Months00
Participants censored- intracranial DOR — 9 Months to <12 Months00
Participants censored- intracranial DOR — 12 Months to <15 Months10
Participants censored- intracranial DOR — 15 Months to <18 Months00
Participants censored- intracranial DOR — 18 Months to <21 Months12
Participants censored- intracranial DOR — 21 Months to <24 Months00
Participants censored- intracranial DOR — >=24 Months61
SecondaryPercentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)

Tumor response was evaluated according to RECIST version 1.1, and disease control: confirmed CR, confirmed PR, or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. CR was defined as disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as 30% or more decrease in SLD of target lesions, taking as reference baseline SLD. Progressive disease: 20% or more increase in SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition to relative increase of 20%, SLD must also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose. Results presented here were based on independent central review.

Time frame:
12 and 24 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1)
Percentage of participantsALK Positive Population (Phase 1)ROS1 Positive Population (Phase 1)
DCR at Week 1253.7 (37.4 to 69.3)58.3 (27.7 to 84.8)
DCR at Week 2439.0 (24.2 to 55.5)50.0 (21.1 to 78.9)
Intracranial DCR at Week 1250.0 (32.4 to 67.6)37.5 (8.5 to 75.5)
Intracranial DCR at Week 2441.2 (24.6 to 59.3)37.5 (8.5 to 75.5)
SecondaryProbability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)

The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either "CNS progression" or "non CNS progression" or "Death") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.

Time frame:
3 years
Reported as:
Number · Probability of events
Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)
Probability of eventsPhase 1 ITT Population
CNS progression0.260
Non CNS progression0.352
Death0.060
SecondaryProgression-Free Survival (PFS) (Phase 1)

PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.

Time frame:
From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)
Reported as:
Median · Months
Progression-Free Survival (PFS) (Phase 1)
MonthsALK Positive Population (Phase 1)ROS1 Positive Population (Phase 1)
Progression-Free Survival (PFS) (Phase 1)5.4 (2.7 to 11.8)10.1 (1.6 to 33.0)
SecondaryOverall Survival (OS) (Phase 1)

OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.

Time frame:
3 years
Reported as:
Median · Months
Overall Survival (OS) (Phase 1)
MonthsALK Positive Population (Phase 1)ROS1 Positive Population (Phase 1)
Overall Survival (OS) (Phase 1)22.3 (11.4 to NA)NA (4.7 to NA)
SecondaryMaximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)

Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)
Nanograms per milliliter (ng/mL)10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)50.80 ± 17149.2 ± 71NA ± NA489.1 ± 45595.5 ± 37760.0 ± 581201 ± 19202.2 ± 57594.9 ± 27507.2 ± 51
SecondaryMaximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)

Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)
ng/mL10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)67.29 ± 18138.1 ± 35359.7 ± 27429.6 ± 48550.2 ± 32541.0 ± 42NA ± NANA ± NA550.0 ± 23600.5 ± 27
SecondaryTime for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)

Tmax of PF-06463922 was observed directly from data as time of first occurrence.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Reported as:
Median · Hours
Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)
Hours10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)1.98 (1.00 to 2.97)2.00 (0.50 to 2.05)1.25 (0.50 to 2.00)1.09 (0.50 to 4.03)1.96 (0.517 to 4.33)1.05 (1.00 to 3.00)2.00 (1.18 to 3.00)1.20 (0.50 to 1.97)1.23 (1.00 to 2.00)2.00 (1.10 to 3.07)
SecondaryTime for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)

Tmax of PF-06463922 was observed directly from data as time of first occurrence.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
Reported as:
Median · Hours
Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Hours10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)1.00 (1.00 to 1.08)1.00 (1.00 to 2.00)2.00 (1.92 to 2.75)1.03 (0.50 to 2.00)1.13 (1.00 to 4.00)1.30 (1.00 to 24.0)1.61 (1.22 to 2.00)0.50 (0.50 to 0.50)0.55 (0.50 to 2.05)2.00 (1.00 to 2.00)
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)

Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups.
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)
Nanogram*hour/milliliter (ng*hr/mL)10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)488.2 ± 211387 ± 35NA ± NA3990 ± 555110 ± 287474 ± 7311410 ± 43982.4 ± 92996 ± 202925 ± 47
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)

Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)
ng*hr/mL10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)752.1 ± 261701 ± 293367 ± 394107 ± 535121 ± 306157 ± 9NA ± NANA ± NA3574 ± 354058 ± 33
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)

AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)
ng*hr/mL10 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)NA ± NANA ± NA7663 ± 798236 ± 2518340 ± 61NA ± NANA ± NA6318 ± 56
SecondaryApparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Reported as:
Geometric mean · Liter/hour (L/hr)
Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)
Liter/hour (L/hr)10 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)NA ± NANA ± NA9.788 ± 7912.14 ± 2510.90 ± 61NA ± NANA ± NA15.83 ± 56
SecondaryApparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)
L/hr10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)13.27 ± 2614.72 ± 2914.84 ± 3917.66 ± 4819.52 ± 3024.37 ± 9NA ± NANA ± NA20.99 ± 3522.37 ± 47
SecondaryApparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)

Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Reported as:
Geometric mean · Liters (L)
Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)
Liters (L)10 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)NA ± NANA ± NA367.9 ± 54356.3 ± 39307.8 ± 41NA ± NANA ± NA378.3 ± 54
SecondaryObserved Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)

Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Reported as:
Mean · Ratio
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Ratio10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)1.543 ± 0.0750561.237 ± 0.208171.105 ± NA1.121 ± 0.445751.071 ± 0.311381.000 ± 0.791370.6500 ± NANA ± NA1.231 ± 0.352281.523 ± 0.29569
SecondaryTerminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)

Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Reported as:
Mean · Hours (hr)
Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)
Hours (hr)10 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)NA ± NA23.70 ± NA27.22 ± 8.296120.89 ± 5.030819.80 ± 3.304525.55 ± NANA ± NA17.18 ± 5.1874
SecondarySteady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)

Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Reported as:
Mean · Ratio
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Ratio10 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)NA ± NA0.5600 ± NA0.6131 ± 0.290210.6603 ± 0.186040.3935 ± NANA ± NANA ± NA0.7687 ± 0.13552
SecondaryRenal Clearance (CLr) of PF-06463922 (Phase 1)

Renal clearance was calculated as Aetau/AUCtau, where Aetau was the cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen).

Time frame:
0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · ml/hour
Renal Clearance (CLr) of PF-06463922 (Phase 1)
ml/hour100 mg QD (Phase 1)
Renal Clearance (CLr) of PF-06463922 (Phase 1)61.31 ± 58
SecondaryPercent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)

Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100\*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.

Time frame:
0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
Reported as:
Mean · Percentage of recovered PF-06463922
Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)
Percentage of recovered PF-06463922100 mg QD (Phase 1)
Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)0.4017 ± 0.11074
SecondaryMaximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)

Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)
ng/mL25 mg QD (Phase 1)150 mg QD (Phase 1)
Day -716.06 ± 4211.56 ± 48
Cycle 1 Day 159.697 ± 405.734 ± 43
SecondaryTime for Cmax (Tmax) of Midazolam (Phase 1)

Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Median · Hours
Time for Cmax (Tmax) of Midazolam (Phase 1)
Hours25 mg QD (Phase 1)150 mg QD (Phase 1)
Day -70.50 (0.50 to 1.00)0.50 (0.50 to 0.50)
Cycle 1 Day 150.50 (0.50 to 1.00)0.50 (0.50 to 0.533)
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)

Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)
ng*hr/mL25 mg QD (Phase 1)150 mg QD (Phase 1)
Day -751.30 ± 4736.49 ± 20
Cycle 1 Day 1520.43 ± 1814.44 ± 25
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)

AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)
ng*hr/mL25 mg QD (Phase 1)150 mg QD (Phase 1)
Day -754.53 ± 43NA ± NA
Cycle 1 Day 1521.32 ± 1816.09 ± 29
SecondaryApparent Oral Clearance (CL/F) of Midazolam (Phase 1)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)
L/hr25 mg QD (Phase 1)150 mg QD (Phase 1)
Day -736.68 ± 43NA ± NA
Cycle 1 Day 1593.86 ± 18124.2 ± 29
SecondaryApparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)

Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)
Liters25 mg QD (Phase 1)150 mg QD (Phase 1)
Day -7229.0 ± 7NA ± NA
Cycle 1 Day 15404.4 ± 51702.2 ± 100
SecondaryTerminal Half-Life of Midazolam (Phase 1)

Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Mean · Hours
Terminal Half-Life of Midazolam (Phase 1)
Hours25 mg QD (Phase 1)150 mg QD (Phase 1)
Day -74.620 ± 1.93285.120 ± NA
Cycle 1 Day 153.343 ± 2.03585.257 ± 5.0639
SecondaryNumber of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)

Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.

Time frame:
Screening (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)
ParticipantsALK Positive Population (Phase 1)
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)14
SecondaryNumber of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)

Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.

Time frame:
Screening (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)
ParticipantsALK Positive Population (Phase 1)
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)7
SecondaryNumber of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)

European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

Time frame:
From start of study treatment until end of treatment (maximum of 8 years approximately)
Reported as:
Count of participants · Participants
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)
ParticipantsPhase 1 PRO Evaluable Population
Improved in global QoL19
Stable in global QoL13
Worsened in global QoL11
Improved in physical functioning5
Stable in physical functioning29
Worsened in physical functioning9
Improved in role functioning14
Stable in role functioning15
Worsened in role functioning14
Improved in emotional functioning15
Stable in emotional functioning21
Worsened in emotional functioning7
Improved in cognitive functioning8
Stable in cognitive functioning21
Worsened in cognitive functioning14
Improved in social functioning13
Stable in social functioning17
Worsened in social functioning13
Improved in fatigue17
Stable in fatigue19
Worsened in fatigue7
Improved in nausea and vomiting10
Stable in nausea and vomiting32
worsened in nausea and vomiting1
Improved in pain17
Stable in pain16
Worsened in pain10
Improved in dyspnea13
Stable in dyspnea19
Worsened in dyspnea11
Improved in insomnia19
Stable in insomnia17
Worsened in insomnia7
Improved in appetite loss14
Stable in appetite loss27
Worsened in appetite loss2
Improved in constipation10
Stable in constipation28
Worsened in constipation5
Improved in diarrhea9
Stable in diarrhea28
Worsened in diarrhea6
Improved in financial difficulties7
Stable in financial difficulties20
Worsened in financial difficulties16
SecondaryNumber of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)

EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

Time frame:
From start of study treatment until end of treatment (maximum of 8 years approximately)
Reported as:
Count of participants · Participants
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)
ParticipantsPhase 1 PRO Evaluable Population
Improved in dyspnea9
Stable in dyspnea23
Worsened in dyspnea11
Improved in coughing23
Stable in coughing12
Worsened in coughing8
Improved in hemoptysis1
Stable in hemoptysis42
Worsened in hemoptysis0
Improved in sore mouth0
Stable in sore mouth40
Worsened in sore mouth3
Improved in dysphagia4
Stable in dysphagia37
Worsened in dysphagia2
Improved in peripheral neuropathy6
Stable in peripheral neuropathy21
Worsened in peripheral neuropathy16
Improved in alopecia4
Stable in alopecia29
Worsened in alopecia9
Improved in chest pain16
Stable in chest pain22
Worsened in chest pain5
Improved in arm or shoulder pain10
Stable in arm or shoulder pain27
Worsened in arm or shoulder pain6
Improved in pain in other parts20
Stable in pain in other parts12
Worsened in pain in other parts11
SecondaryChange From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)

In Phase 1, the MMSE was collected to assess mental status. The MMSE is a 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30 and minimum score is 0. Highest score indicates no cognitive impairment, lowest score indicates severe cognitive impairment. The MMSE was removed under Amendment 6 of the study protocol, and not required for Phase 2, as the tool was not considered meaningful for assessment of cognitive function.

Time frame:
Baseline, Day 1 of Cycle 1-52, and end of treatment (up to 3 years)
Reported as:
Mean · Units on a scale
Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)
Units on a scale10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)
Cycle 1 Day 11.0 ± 1.41—-0.5 ± 0.71-0.9 ± 2.270.8 ± 1.39———0.0 ± NA0.0 ± NA
Cycle 2 Day 12.0 ± NA-0.3 ± 0.582.0 ± NA0.3 ± 1.410.0 ± 1.794.7 ± 8.084.0 ± 4.240.0 ± 0.000.0 ± 0.00-0.3 ± 1.15
Cycle 3 Day 12.0 ± 0.000.3 ± 0.58-0.5 ± 0.71-0.6 ± 1.850.2 ± 1.525.0 ± 8.493.0 ± 2.83—0.0 ± NA-1.0 ± 1.00
Cycle 4 Day 15.0 ± NA0.5 ± 0.711.5 ± 2.12-1.1 ± 1.810.0 ± 1.472.0 ± 6.24-0.5 ± 3.54—0.0 ± NA-0.7 ± 1.15
Cycle 5 Day 10.5 ± 3.540.5 ± 0.711.5 ± 2.120.3 ± 1.25-0.2 ± 1.724.7 ± 8.140.5 ± 6.36—0.0 ± NA-0.5 ± 0.71
Cycle 6 Day 12.5 ± 2.120.5 ± 0.711.0 ± 1.41-0.4 ± 2.700.3 ± 0.904.3 ± 5.862.0 ± 4.24—0.0 ± NA-1.3 ± 2.31
Cycle 7 Day 12.0 ± NA0.5 ± 0.711.5 ± 2.12-0.1 ± 1.210.4 ± 0.904.7 ± 8.333.0 ± 4.24—0.0 ± NA-0.7 ± 1.15
Cycle 8 Day 1-4.0 ± NA0.5 ± 0.711.5 ± 2.12-0.1 ± 2.340.2 ± 1.343.0 ± 7.814.0 ± 4.24—0.0 ± NA0.0 ± 0.00
Cycle 9 Day 1—0.0 ± 0.000.0 ± NA-1.0 ± 2.310.3 ± 2.106.0 ± 8.496.0 ± NA——-0.3 ± 0.58
Cycle 10 Day 1-5.0 ± NA0.5 ± 0.710.0 ± NA0.0 ± 0.00-0.1 ± 0.886.5 ± 9.196.0 ± NA—0.0 ± NA-1.7 ± 1.53
Cycle 11 Day 1—-0.5 ± 0.710.0 ± NA0.3 ± 1.70-0.2 ± 1.537.0 ± 8.493.5 ± 3.54—0.0 ± NA0.0 ± 0.00
Cycle 12 Day 1—0.5 ± 0.71—-0.6 ± 2.19-0.2 ± 2.336.5 ± 9.193.5 ± 3.54—0.0 ± NA-0.7 ± 0.58
Cycle 13 Day 1—0.5 ± 0.71—0.8 ± 1.790.5 ± 2.225.5 ± 7.783.0 ± 4.24—0.0 ± NA-0.5 ± 0.71
Cycle 14 Day 1—0.5 ± 0.71—-0.3 ± 3.200.3 ± 0.796.0 ± 8.492.5 ± 3.54—0.0 ± NA0.0 ± 0.00
Cycle 15 Day 1—0.5 ± 0.71—-1.7 ± 5.430.1 ± 1.36—4.0 ± 4.24—0.0 ± NA-0.3 ± 0.58
Cycle 16 Day 1—0.0 ± 1.41—-0.2 ± 2.49-0.2 ± 1.991.0 ± NA1.5 ± 6.36—0.0 ± NA0.0 ± 0.00
Cycle 17 Day 1—-2.0 ± 2.83—0.6 ± 1.950.1 ± 1.17-3.0 ± NA4.0 ± 4.24—0.0 ± NA-1.3 ± 1.53
Cycle 18 Day 1—-0.5 ± 0.71—0.8 ± 1.790.0 ± 1.73-2.0 ± NA3.0 ± 4.24——0.0 ± 0.00
Cycle 19 Day 1—-0.5 ± 0.71—0.8 ± 1.79-0.6 ± 2.650.0 ± NA3.5 ± 4.95—0.0 ± NA-0.5 ± 0.71
Cycle 20 Day 1—0.0 ± 0.00—0.0 ± 1.410.7 ± 2.120.0 ± NA3.5 ± 3.54—0.0 ± NA-0.5 ± 0.71
Cycle 21 Day 1—-0.5 ± 0.71—0.0 ± 1.410.1 ± 2.09—4.0 ± 4.24—0.0 ± NA-0.5 ± 0.71
Cycle 22 Day 1—0.0 ± 0.00—0.4 ± 1.520.1 ± 1.450.0 ± NA3.5 ± 3.54—-1.0 ± NA-0.3 ± 0.58
Cycle 23 Day 1—0.5 ± 0.71—0.0 ± 1.410.1 ± 1.81-1.0 ± NA1.5 ± 3.54—0.0 ± NA-2.3 ± 4.04
Cycle 24 Day 1—0.5 ± 0.71—-0.4 ± 0.890.6 ± 0.741.0 ± NA1.5 ± 4.95—0.0 ± NA0.0 ± 0.00
Cycle 25 Day 1—0.0 ± 0.00—0.8 ± 1.79-0.9 ± 2.27-2.0 ± NA2.5 ± 4.95—0.0 ± NA0.0 ± 0.00
Cycle 26 Day 1—0.5 ± 0.71—0.8 ± 1.79-0.4 ± 2.77-1.0 ± NA2.0 ± 4.24—0.0 ± NA-0.3 ± 0.58
Cycle 27 Day 1—0.5 ± 0.71—0.8 ± 1.79-0.1 ± 2.67-1.0 ± NA3.5 ± 3.54—0.0 ± NA-1.0 ± 1.41
Cycle 28 Day 1—0.5 ± 0.71—1.0 ± 2.000.7 ± 0.76-2.0 ± NA3.0 ± 2.83—0.0 ± NA0.0 ± 0.00
Cycle 29 Day 1—-1.5 ± 2.12—0.5 ± 1.730.1 ± 1.810.0 ± NA3.5 ± 3.54—0.0 ± NA0.0 ± 0.00
Cycle 30 Day 1—0.0 ± 0.00—0.8 ± 1.500.4 ± 0.550.0 ± NA3.0 ± 2.83—0.0 ± NA-1.0 ± 1.00
Cycle 31 Day 1—0.5 ± 0.71—1.0 ± 2.650.7 ± 0.820.0 ± NA3.0 ± 4.24——0.0 ± 0.00
Cycle 32 Day 1—0.0 ± 0.00—1.3 ± 2.310.4 ± 0.55—3.5 ± 3.54—0.0 ± NA0.0 ± 0.00
Cycle 33 Day 1—0.0 ± 0.00—1.3 ± 2.310.5 ± 0.58—3.5 ± 3.54—0.0 ± NA0.0 ± 0.00
Cycle 34 Day 1—0.0 ± 0.00—0.0 ± 0.000.3 ± 0.50—4.0 ± 4.24—0.0 ± NA0.0 ± 0.00
Cycle 35 Day 1—0.5 ± 0.71—0.0 ± NA0.3 ± 0.50—4.0 ± 4.24—0.0 ± NA0.0 ± NA
Cycle 36 Day 1—-0.5 ± 0.71—0.0 ± NA0.0 ± 0.00—4.0 ± 4.24—0.0 ± NA0.0 ± NA
Cycle 37 Day 1—0.0 ± 0.00—-1.0 ± NA0.0 ± 0.00—3.5 ± 4.95———
Cycle 38 Day 1—0.0 ± 0.00—0.0 ± NA0.0 ± 0.00—3.0 ± 2.83—0.0 ± NA—
Cycle 39 Day 1—0.0 ± NA—0.0 ± NA-0.5 ± 0.71—3.5 ± 4.95———
Cycle 40 Day 1—0.5 ± 0.71—-1.0 ± NA0.0 ± NA—4.0 ± 4.24———
Cycle 41 Day 1—0.5 ± 0.71—0.0 ± NA0.0 ± NA—1.5 ± 6.36———
Cycle 42 Day 1—-0.5 ± 0.71—0.0 ± NA0.0 ± NA—4.0 ± 4.24———
Cycle 43 Day 1—0.0 ± 0.00—0.0 ± NA——4.0 ± 4.24———
Cycle 44 Day 1—1.0 ± NA—-1.0 ± NA——3.0 ± 4.24———
Cycle 45 Day 1—1.0 ± NA—0.0 ± NA——1.0 ± NA———
Cycle 46 Day 1—0.0 ± NA—-1.0 ± NA——————
Cycle 47 Day 1—0.0 ± NA—0.0 ± NA——————
Cycle 48 Day 1—-3.0 ± NA—0.0 ± NA——————
Cycle 49 Day 1—0.5 ± 0.71————————
Cycle 50 Day 1—-3.0 ± NA————————
Cycle 51 Day 1—-0.5 ± 0.71————————
Cycle 52 Day 1—1.0 ± NA————————
End of treatment-8.0 ± NA—0.7 ± 1.15-2.0 ± NA-2.3 ± 5.19———-15.0 ± NA0.0 ± NA
SecondaryTime to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI Sub-study)

Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

Time frame:
From first dose of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Median · Months
Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI Sub-study)
MonthsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
TTR1.4 (1.2 to 5.4)1.4 (1.2 to 18.0)1.4 (1.1 to 16.6)2.6 (1.2 to 16.4)1.4 (1.2 to 9.3)1.4 (1.3 to 29.7)1.4 (1.2 to 11.0)
Intracranial TTR2.1 (1.2 to 2.8)1.4 (1.2 to 1.5)1.4 (1.1 to 5.7)1.7 (1.2 to 17.5)1.4 (1.2 to 10.6)1.4 (1.2 to 28.9)2.0 (1.1 to 4.2)
SecondaryDuration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy)

Duration of response(DOR): time from first documentation of objective tumor response (CR/PR) to first documentation of PD or to death due to any cause, whichever occurred first. DOR: calculated for subgroup of participants with confirmed objective tumor response. Intracranial DOR: calculated for participants with confirmed intracranial objective response. CR:disappearance of all non-lymph node target lesions (where all target lesions are recorded with length of 0mm on Target Lesion eCRF). Any pathological lymph node (recorded as target lesion) must have reduction in short axis to \<10mm. PR:30% or more decrease in SLD of target lesion, taking as reference baseline SLD. PD:20% or more increase in the SLD of target lesions relative to baseline or smallest SLD (nadir) recorded since first dose. In addition, also demonstrate absolute increase of at least 5mm (\>=5mm) relative to baseline or smallest SLD (nadir) recorded since first dose.

Time frame:
From first dose of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Median · Months
Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy)
MonthsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
DOR17.16 (12.45 to 35.09)16.56 (4.20 to NA)11.10 (5.55 to NA)15.08 (5.55 to 26.28)7.03 (4.17 to 11.01)19.61 (11.10 to NA)5.19 (4.17 to NA)
Intra-cranial DORNA (8.28 to NA)NA (20.99 to NA)37.12 (8.38 to NA)14.52 (11.07 to NA)10.32 (6.90 to 14.98)17.62 (4.99 to NA)NA (2.76 to NA)
SecondaryPercentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy)

Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed CR, confirmed PR, or stable disease (SD). CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. SD= when neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD is observed, taking as reference the smallest sum diameters while on study. Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.

Time frame:
Weeks 12 and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy)
Percentage of participantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Disease control rate at Week 1293.3 (77.9 to 99.2)85.2 (66.3 to 95.8)68.3 (55.0 to 79.7)64.6 (51.8 to 76.1)50.0 (34.9 to 65.1)66.0 (50.7 to 79.1)56.3 (37.7 to 73.6)
Disease control rate at Week 2483.3 (65.3 to 94.4)63.0 (42.4 to 80.6)51.7 (38.4 to 64.8)49.2 (36.6 to 61.9)32.6 (19.5 to 48.0)48.9 (34.1 to 63.9)34.4 (18.6 to 53.2)
Intra-cranial disease control rate at Week 1287.5 (47.3 to 99.7)94.1 (71.3 to 99.9)75.8 (57.7 to 88.9)75.6 (60.5 to 87.1)67.6 (50.2 to 82.0)72.0 (50.6 to 87.9)56.3 (29.9 to 80.2)
Intra-cranial disease control rate at Week 2475.0 (34.9 to 96.8)70.6 (44.0 to 89.7)60.6 (42.1 to 77.1)62.2 (46.5 to 76.2)48.6 (31.9 to 65.6)52.0 (31.3 to 72.2)43.8 (19.8 to 70.1)
SecondaryTime to Progression on the Last Prior Therapy (Phase 2)

TTP on the last prior therapy was defined as time from the first dose date of the last prior treatment regimen to the date of progression. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose.

Time frame:
From first dose of study treatment to the date of progression (maximum of 7.5 years for Phase 2)
Reported as:
Median · Months
Time to Progression on the Last Prior Therapy (Phase 2)
MonthsEXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)
Prior systemic therapy before PF-0646392211.5 (7.2 to 19.6)12.8 (10.9 to 16.9)10.2 (7.6 to 15.9)3.7 (2.1 to 6.4)
Prior ALK+/ROS1+ TKI treatment11.5 (7.2 to 19.6)13.8 (11.2 to 18.1)12.1 (7.9 to 16.4)3.7 (2.1 to 6.6)
Prior systemic therapy other than ALK+/ROS1+ TKI19.6 (16.1 to NA)8.5 (5.0 to 12.6)5.0 (3.1 to 10.0)5.6 (3.5 to 11.2)
SecondaryTime to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy)

Time to progression (TTP) was defined as the time from the first dose of study treatment to the first documentation of objective PD. Intracranial TTP was defined as the time from the first dose of study treatment to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.

Time frame:
From first dose of study treatment to the first documentation of objective PD (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Median · Months
Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy)
MonthsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
TTP17.7 (12.5 to 40.5)20.6 (5.5 to NA)8.2 (5.5 to 12.5)8.4 (5.6 to 13.7)5.6 (4.0 to 8.3)12.5 (8.2 to 26.2)5.7 (4.1 to 8.3)
Intracranial TTPNA (NA to NA)NA (NA to NA)NA (15.0 to NA)22.1 (15.7 to NA)16.4 (12.7 to NA)NA (34.5 to NA)NA (6.9 to NA)
SecondaryProbability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)

Probability of first event being CNS progression, non-CNS progression, or death was evaluated with competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to analysis set. Time to first event being Competing Event (either "CNS progression" or "non CNS progression" or "Death") = time from first dose until date of that specific event. Participants not known to have any of Competing Events were censored on date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as competing cause of failure for analysis of other type of events. For each type of event, cumulative incidence function corresponding to nearest time point preceding 1 year is presented. PD:20% or more increase in SLD of target lesion relative to baseline or smallest SLD (nadir) recorded since first dose. SLD must demonstrate absolute increase of atleast 5mm(\>=5 mm) relative to baseline or smallest SLD (nadir) recorded since first dose.

Time frame:
From first dose of study treatment until first event of CNS progression (maximum of 7.5 years for Phase 2)
Reported as:
Number · Probability of events
Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)
Probability of eventsPhase 2 ITT Population
CNS progression0.179
Non CNS progression0.325
Death0.055
SecondaryProgression-Free Survival (PFS) (Phase 2 and DDI Substudy)

PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.

Time frame:
From first dose of study treatment to first documentation of objective PD or death due to any cause, whichever came first (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Median · Months
Progression-Free Survival (PFS) (Phase 2 and DDI Substudy)
MonthsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Progression-Free Survival (PFS) (Phase 2 and DDI Substudy)16.6 (11.8 to 28.3)20.6 (5.5 to NA)6.9 (5.5 to 11.0)7.3 (4.2 to 11.1)5.5 (3.9 to 8.2)9.9 (5.5 to 21.0)5.7 (4.0 to 7.1)
SecondaryOverall Survival (Phase 2 and DDI Substudy)

OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.

Time frame:
From first dose of study treatment until date of death (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Median · Months
Overall Survival (Phase 2 and DDI Substudy)
MonthsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Overall Survival (Phase 2 and DDI Substudy)NA (NA to NA)52.5 (24.4 to NA)NA (38.5 to NA)18.7 (15.1 to 34.1)20.4 (10.5 to 31.6)49.7 (21.0 to NA)19.8 (11.1 to NA)
SecondaryMaximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)

Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)
ng/mLPhase 2 and Japan LIC PK Analysis Set
Day -7695.2 ± 40
Cycle 1 Day 15576.5 ± 42
SecondaryTime for Cmax (Tmax) of PF-06463922 (Phase 2)

Tmax of PF-06463922 was observed directly from data as time of first occurrence.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Median · Hours
Time for Cmax (Tmax) of PF-06463922 (Phase 2)
HoursPhase 2 and Japan LIC PK Analysis Set
Day -71.15 (0.50 to 4.02)
Cycle 1 Day 151.96 (0.50 to 22.7)
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)

AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Reported as:
Geometric mean · ng*hour/mL
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)
ng*hour/mLPhase 2 and Japan LIC PK Analysis Set
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)9088 ± 35
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)

Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · ng*hour/mL
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)
ng*hour/mLPhase 2 and Japan LIC PK Analysis Set
Day -75308 ± 36
Cycle 1 Day 155650 ± 39
SecondaryApparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Geometric mean · Liter/hour
Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)
Liter/hourPhase 2 and Japan LIC PK Analysis Set
Day -711.01 ± 35
Cycle 1 Day 1517.70 ± 39
SecondaryApparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)

Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf\*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)
LitersPhase 2 and Japan LIC PK Analysis Set
Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)351.5 ± 37
SecondaryTerminal Half-Life of PF-06463922 (Phase 2)

Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Reported as:
Mean · Hours
Terminal Half-Life of PF-06463922 (Phase 2)
HoursPhase 2 and Japan LIC PK Analysis Set
Terminal Half-Life of PF-06463922 (Phase 2)23.58 ± 9.3743
SecondaryObserved Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)

Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2).

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Mean · Ratio
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)
RatioPhase 2 and Japan LIC PK Analysis Set
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)1.082 ± 0.42701
SecondarySteady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)

Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Reported as:
Mean · Ratio
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)
RatioPhase 2 and Japan LIC PK Analysis Set
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)0.6577 ± 0.28627
SecondaryNumber of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)

Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented.

Time frame:
Screening (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)
ParticipantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)0681714
SecondaryNumber of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)

Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.

Time frame:
Screening (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)
ParticipantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)0781213
SecondaryNumber of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study)

European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

Time frame:
From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study)
ParticipantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Improved in global QoL17111825171912
Stable in global QoL10122422161518
Worsened in global QoL3313131062
Missing for global QoL0000010
Improved in physical functioning11813248115
Stable in physical functioning13173824252323
Worsened in physical functioning614121064
Missing for physical functioning0000010
Improved in role functioning1271525181710
Stable in role functioning9163318131715
Worsened in role functioning937171257
Missing for role functioning0000020
Improved in emotional functioning13121320171610
Stable in emotional functioning13143234202220
Worsened in emotional functioning40106622
Missing for emotional functioning0000010
Improved in cognitive functioning9451212129
Stable in cognitive functioning12143634192011
Worsened in cognitive functioning98141412812
Missing for cognitive functioning0000010
Improved in social functioning1471620111313
Stable in social functioning11163329211813
Worsened in social functioning536111196
Missing for social functioning0000010
Improved in fatigue18142228261617
Stable in fatigue81125239209
Worsened in fatigue4189846
Missing for fatigue0000010
Improved in nausea and vomiting85101613106
Stable in nausea and vomiting22214439282824
Worsened in nausea and vomiting0015222
Missing for nausea and vomiting0000010
Improved in pain13102023192114
Stable in pain10142528191213
Worsened in pain72109575
Missing for pain0000010
Improved in dyspnea1610102314149
Stable in dyspnea10143322181715
Worsened in dyspnea4212151198
Missing for dyspnea0000010
Improved in insomnia2081830211912
Stable in insomnia9132822161815
Worsened in insomnia1598635
Missing for insomnia0000010
Improved in appetite loss1441829222010
Stable in appetite loss16223626212020
Worsened in appetite loss0015002
Missing for appetite loss0000010
Improved in constipation105916111310
Stable in constipation14193333292212
Worsened in constipation6213113510
Missing for constipation0000010
Improved in diarrhea5310101086
Stable in diarrhea18214039272821
Worsened in diarrhea72511645
Missing for diarrhea0000010
Improved in financial difficulties106111310109
Stable in financial difficulties17193438222616
Worsened in financial difficulties311091147
Missing for financial difficulties0000010
SecondaryNumber of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study)

EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.

Time frame:
From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study)
ParticipantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Improved in dyspnea11592112126
Stable in dyspnea16183625212318
Worsened in dyspnea331014968
Missing-dyspnea0000100
Improved in coughing1892226181716
Stable in coughing9132628151815
Worsened in coughing3476961
Missing-coughing0000100
Improved in hemoptysis4075541
Stable in hemoptysis24254752343631
Worsened in hemoptysis2113310
Missing-hemoptysis0000100
Improved in sore mouth0249254
Stable in sore mouth25204441332826
Worsened in sore mouth54710782
Missing-sore mouth0000100
Improved in dysphagia3137453
Stable in dysphagia23244648333027
Worsened in dysphagia4165562
Missing-dysphagia0000100
Improved in peripheral neuropathy4595699
Stable in peripheral neuropathy10132733221816
Worsened in peripheral neuropathy168192214147
Missing-peripheral neuropathy0000100
Improved in alopecia212101094
Stable in alopecia18224140242721
Worsened in alopecia1031210857
Missing-alopecia0000100
Improved in chest pain1171318141413
Stable in chest pain17173533252417
Worsened in chest pain2269332
Missing-chest pain0010100
Improved in arm or shoulder pain105141412129
Stable in arm or shoulder pain15193036212219
Worsened in arm or shoulder pain521110974
Missing- arm or shoulder pain0000100
Improved in pain in other parts96172015179
Stable in pain in other parts1415232491810
Worsened in pain in other parts75151617612
Missing-Pain in other parts0000201
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study)

AE: any untoward medical occurrence in clinical investigation participant administered a product or medical device, regardless of causal relationship to study treatment. Treatment-emergent AEs (TEAEs): AEs which occurred for first time during effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs): any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of ability to conduction normal life function). AEs included SAEs and non-serious AEs. Severity was graded as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Grade1: mild, Grade2: moderate, Grade3: severe, Grade4: Life threatening consequences; urgent intervention indicated, Grade 5: death related to AE.

Time frame:
From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study)
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
AEs (all causality)33312173333430275965464732
AEs (treatment-related)33311163313430275661434531
SAEs (all causality)3216103222215113431232113
SAEs (treatment-related)11011300013086641
Grade 3 or 4 (all causality)3306123221422224350363624
Grade 3 or 4 (treatment-related)220362001313153131222516
Grade 5 (all causality)1101420010331011975
Grade 5 (treatment-related)00000000000000000
SecondaryNumber of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Hematology

Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Hematology parameters with any abnormalities were reported in this outcome measure.

Time frame:
From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Hematology
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Anemia33310163333424225152353425
Hemoglobin increased00000000000013211
Lymphocyte count decreased222743300212143031212615
Lymphocyte count increased00003100004361102
Neutrophil count decreased100420100173810273
Platelet count decreased2204510001810181213138
White blood cell decreased2104222001959138104
SecondaryNumber of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Chemistry

Chemistry evaluation included alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), blood bilirubin, creatine phosphokinase (CPK), creatinine, gamma-glutamyl transferase (GGT), calcium, sodium, potassium, magnesium, albumin, glucose (non-fasted), albumin, phosphorus or phosphate, serum amylase and lipase.

Time frame:
From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Chemistry
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
ALT increased211692200313152525161510
Alkaline phosphatase increased113610310231013292725149
AST increased222582201316153633211811
Blood bilirubin increased10010000011031211
CPK increased————11——1—2131—21
Creatinine increased32310133322328224048343720
GGT increased0———101—021321010
Hypercalcemia00003100018478425
Hyperglycemia332782112117183748343123
Hyperkalemia012361111211132113765
Hypermagnesemia20022000003222140
Hypernatremia01004200016695453
Hypoalbuminemia213473113119203743322918
Hypocalcemia1014521001551696126
Hypoglycemia001340101014109636
Hypokalemia002433110211210128147
Hypomagnesemia0124230113692320161515
Hyponatremia2112411022791523121210
Hypophosphatemia12033211218923198159
Lipase increased3008601022107141615187
Serum amylase increased3002501002136182011154
SecondaryNumber of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Coagulation, Lipids and Urinalysis

Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included Cholesterol and triglycerides.

Time frame:
From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Coagulation, Lipids and Urinalysis
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Activated partial thromboplastin time prolonged10132000002131342
Cholesterol high22210162332330265864454431
Hypertriglyceridemia02211162321330265661454331
INR increased21122100001236273
Prothrombin time21133100111366366
SecondaryNumber of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)

Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured.

Time frame:
From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Increase in sitting SBP >=40 mmHg0000320010971010544
Increase in sitting SBP >=60 mmHg00000000000002000
Decrease in sitting SBP >=40 mmHg00032100000252231
Decrease in sitting SBP >=60 mmHg00000000000000000
Increase in sitting DBP >=20 mmHg02007310101112211515127
Increase in sitting DBP >=40 mmHg00000000001311020
Decrease in sitting DBP >=20 mmHg21053220129515101098
Decrease in sitting DBP >=40 mmHg00000000000000010
Sitting pulse rate <50 bpm01000000001251022
Sitting pulse rate >120 bpm00112200002159423
Increase in sitting pulse rate >=30 bpm010271000107141917178
Decrease in sitting pulse rate >=30 bpm001201011211287354
Increase in weight: 10% to <20%1008622000914171511149
Increase in weight: >=20%02115100111221016993
Decrease in weight >=10%00000000022134221
SecondaryNumber of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study)

Left Ventricular Ejection Fraction (LVEF) was determined by echocardiogram. Baseline was defined as the measurement prior to the first dose of study treatment.

Time frame:
From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study)
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study)1013521002421314352
SecondaryNumber of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)

Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia's formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment.

Time frame:
From first dose of study treatment to end of treatment (maximum of 8 years for Phase 1, maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study)
Participants10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Sub-study
QTcF: 450 to <480 msec1002110201581191397
QTcF: 480 to <500 msec10000000011130111
QTcF: >=500 msec00000000000011101
QTcF Increase: 30 to <60 msec001330010110818207127
QTcF: >=60 msec00000000010011311
SecondaryNumber of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)

The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide. Maximum score of 4 or 5 indicates maximum suicidal ideation and minimum score of "0" indicates no suicidal ideation.

Time frame:
From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2)
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)
ParticipantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Suicidal ideation102112
Suicidal behavior000001
SecondaryChange From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)

The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3, where 0 indicated lowest depression and 3 indicated severe depression). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.

Time frame:
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)
Units on a scaleEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Cycle 2 Day 1-2.59 (-4.82 to -0.37)-3.27 (-5.52 to -1.01)-2.26 (-3.77 to -0.76)-2.17 (-3.89 to -0.46)-1.52 (-3.60 to 0.56)-2.43 (-4.57 to -0.29)
Cycle 3 Day 1-3.34 (-5.57 to -1.12)-3.18 (-5.43 to -0.93)-3.03 (-4.55 to -1.51)-3.10 (-4.85 to -1.35)-0.46 (-2.61 to 1.69)-1.24 (-3.37 to 0.90)
Cycle 4 Day 1-3.84 (-6.07 to -1.62)-4.10 (-6.38 to -1.82)-2.59 (-4.14 to -1.05)-1.95 (-3.72 to -0.19)-1.19 (-3.38 to 1.01)-1.94 (-4.12 to 0.24)
Cycle 5 Day 1-4.47 (-6.69 to -2.24)-3.96 (-6.27 to -1.66)-2.75 (-4.33 to -1.16)-3.03 (-4.82 to -1.25)-1.51 (-3.74 to 0.72)-1.25 (-3.46 to 0.95)
Cycle 6 Day 1-3.51 (-5.73 to -1.28)-4.25 (-6.56 to -1.94)-3.31 (-4.90 to -1.72)-3.79 (-5.61 to -1.98)-0.42 (-2.64 to 1.81)-0.29 (-2.54 to 1.96)
Cycle 8 Day 1-4.17 (-6.41 to -1.92)-4.86 (-7.23 to -2.50)-2.26 (-3.86 to -0.66)-4.06 (-5.90 to -2.22)-1.09 (-3.34 to 1.17)0.17 (-2.10 to 2.45)
Cycle 10 Day 1-3.09 (-5.38 to -0.80)-4.92 (-7.28 to -2.55)-1.94 (-3.54 to -0.34)-4.27 (-6.14 to -2.39)-2.97 (-5.29 to -0.66)-0.19 (-2.60 to 2.22)
Cycle 12 Day 1-3.95 (-6.30 to -1.61)-5.60 (-7.97 to -3.24)-0.72 (-2.40 to 0.95)-4.80 (-6.83 to -2.77)-1.94 (-4.29 to 0.42)-1.40 (-3.81 to 1.01)
Cycle 14 Day 1-3.81 (-6.18 to -1.43)-5.80 (-8.35 to -3.25)-2.58 (-4.41 to -0.76)-4.29 (-6.41 to -2.17)-1.73 (-4.40 to 0.94)-0.08 (-2.59 to 2.42)
Cycle 16 Day 1-1.75 (-4.40 to 0.89)-4.61 (-7.51 to -1.71)-2.15 (-4.35 to 0.06)-4.65 (-6.90 to -2.41)-2.22 (-5.50 to 1.07)0.03 (-2.65 to 2.71)
Cycle 18 Day 1-4.49 (-7.49 to -1.49)-7.02 (-10.59 to -3.46)-1.96 (-4.22 to 0.31)-2.86 (-5.21 to -0.51)-1.11 (-8.25 to 6.03)1.88 (-1.66 to 5.41)
Cycle 20 Day 1-5.01 (-8.55 to -1.46)-5.17 (-9.06 to -1.29)-1.82 (-4.70 to 1.06)-3.63 (-6.31 to -0.95)—1.88 (-1.66 to 5.41)
Cycle 22 Day 1-2.93 (-6.79 to 0.94)-4.63 (-9.00 to -0.26)-2.36 (-5.68 to 0.96)-5.50 (-8.87 to -2.12)—-2.39 (-6.73 to 1.94)
Cycle 24 Day 1-7.31 (-11.66 to -2.96)-5.63 (-10.00 to -1.26)-2.88 (-7.04 to 1.28)-3.89 (-8.10 to 0.32)—2.27 (-2.06 to 6.61)
Cycle 26 Day 1-5.50 (-10.67 to -0.33)—-3.03 (-10.01 to 3.95)-4.30 (-11.31 to 2.70)——
End of treatment-4.77 (-9.23 to -0.32)-0.73 (-5.61 to 4.15)-2.55 (-5.28 to 0.18)-3.22 (-5.49 to -0.95)0.74 (-2.70 to 4.17)-2.08 (-5.65 to 1.50)
SecondaryChange From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)

The Detection Test is a measure of psychomotor function and uses a well validated simple reaction time paradigm with playing card stimuli. In this test, the on-screen instructions ask: "Has the card turned over?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as the card flips over the participant must press "Yes". The participant is encouraged to work as quickly as they can and be as accurate as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

Time frame:
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)
Units on a scaleEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Cycle 2 Day 10.01 (-0.04 to 0.05)0.04 (-0.01 to 0.08)-0.01 (-0.04 to 0.02)0.02 (-0.01 to 0.05)-0.02 (-0.05 to 0.02)0.01 (-0.03 to 0.05)
Cycle 3 Day 1-0.01 (-0.05 to 0.03)0.01 (-0.03 to 0.05)0.01 (-0.02 to 0.04)-0.01 (-0.04 to 0.02)-0.01 (-0.05 to 0.02)-0.01 (-0.05 to 0.03)
Cycle 4 Day 10.03 (-0.02 to 0.07)0.00 (-0.04 to 0.04)-0.03 (-0.06 to 0.00)-0.02 (-0.05 to 0.01)-0.04 (-0.07 to -0.00)-0.01 (-0.06 to 0.03)
Cycle 5 Day 1-0.01 (-0.05 to 0.03)-0.01 (-0.06 to 0.03)-0.00 (-0.03 to 0.03)0.00 (-0.03 to 0.03)-0.04 (-0.08 to -0.01)-0.04 (-0.08 to 0.00)
Cycle 6 Day 1-0.03 (-0.07 to 0.01)0.01 (-0.03 to 0.06)-0.02 (-0.05 to 0.01)-0.00 (-0.04 to 0.03)-0.01 (-0.05 to 0.02)-0.02 (-0.07 to 0.02)
Cycle 8 Day 1-0.02 (-0.06 to 0.02)0.00 (-0.04 to 0.05)-0.02 (-0.05 to 0.01)-0.03 (-0.06 to 0.01)-0.04 (-0.07 to 0.00)0.00 (-0.04 to 0.05)
Cycle 10 Day 1-0.02 (-0.06 to 0.02)0.03 (-0.01 to 0.08)-0.02 (-0.06 to 0.01)-0.01 (-0.05 to 0.02)-0.05 (-0.09 to -0.01)-0.04 (-0.08 to 0.01)
Cycle 12 Day 1-0.04 (-0.08 to 0.01)-0.00 (-0.05 to 0.04)-0.02 (-0.06 to 0.02)-0.03 (-0.06 to 0.01)-0.08 (-0.13 to -0.04)-0.01 (-0.05 to 0.04)
Cycle 14 Day 10.02 (-0.04 to 0.07)0.02 (-0.03 to 0.08)-0.05 (-0.09 to -0.01)-0.04 (-0.08 to -0.00)-0.02 (-0.07 to 0.04)0.01 (-0.05 to 0.06)
Cycle 16 Day 1-0.03 (-0.09 to 0.03)0.01 (-0.05 to 0.07)0.02 (-0.03 to 0.07)-0.03 (-0.08 to 0.01)-0.04 (-0.14 to 0.06)-0.01 (-0.07 to 0.06)
Cycle 18 Day 10.09 (0.01 to 0.18)-0.02 (-0.09 to 0.05)-0.03 (-0.09 to 0.02)-0.06 (-0.11 to -0.01)-0.09 (-0.23 to 0.04)-0.01 (-0.08 to 0.05)
Cycle 20 Day 10.07 (-0.03 to 0.17)0.02 (-0.06 to 0.09)0.01 (-0.06 to 0.08)-0.09 (-0.16 to -0.03)—-0.03 (-0.11 to 0.04)
Cycle 22 Day 1-0.02 (-0.12 to 0.08)-0.02 (-0.10 to 0.07)0.00 (-0.08 to 0.08)-0.08 (-0.16 to 0.00)—-0.05 (-0.13 to 0.03)
Cycle 24 Day 10.03 (-0.11 to 0.16)——-0.06 (-0.20 to 0.07)——
End of treatment-0.04 (-0.13 to 0.04)-0.01 (-0.10 to 0.08)-0.02 (-0.08 to 0.04)-0.05 (-0.10 to -0.00)-0.07 (-0.14 to -0.01)-0.05 (-0.12 to 0.03)
SecondaryChange From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)

The Identification Test is a measure of visual attention and uses a well validated choice reaction time paradigm with playing card stimuli. In this task, the playing cards are all red or black jokers. The on-screen instructions ask: "Is the card red?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as it flips over the participant must decide whether the card is red or not. If it is red the participant should press "Yes", and if it is not red the participant should press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

Time frame:
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)
Units on a scaleEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Cycle 2 Day 1-0.02 (-0.05 to 0.01)-0.02 (-0.05 to 0.01)-0.01 (-0.03 to 0.00)-0.01 (-0.03 to 0.01)-0.02 (-0.04 to 0.01)-0.01 (-0.04 to 0.02)
Cycle 3 Day 1-0.01 (-0.04 to 0.02)-0.01 (-0.04 to 0.02)-0.02 (-0.04 to 0.00)-0.02 (-0.04 to 0.00)-0.02 (-0.05 to 0.00)-0.01 (-0.04 to 0.02)
Cycle 4 Day 1-0.02 (-0.05 to 0.01)-0.01 (-0.04 to 0.01)-0.02 (-0.04 to 0.00)-0.03 (-0.05 to -0.01)-0.05 (-0.08 to -0.03)-0.02 (-0.04 to 0.01)
Cycle 5 Day 1-0.03 (-0.06 to -0.00)-0.02 (-0.05 to 0.01)-0.03 (-0.05 to -0.00)-0.02 (-0.04 to 0.01)-0.05 (-0.07 to -0.02)-0.02 (-0.05 to 0.00)
Cycle 6 Day 1-0.04 (-0.07 to -0.01)-0.02 (-0.05 to 0.01)-0.02 (-0.04 to 0.00)-0.03 (-0.06 to -0.01)-0.03 (-0.06 to -0.01)-0.03 (-0.06 to -0.00)
Cycle 8 Day 1-0.03 (-0.06 to -0.00)-0.02 (-0.05 to 0.01)-0.03 (-0.05 to -0.01)-0.03 (-0.05 to -0.01)-0.05 (-0.07 to -0.02)-0.03 (-0.06 to 0.00)
Cycle 10 Day 1-0.03 (-0.06 to 0.00)-0.01 (-0.04 to 0.02)-0.03 (-0.05 to -0.01)-0.02 (-0.05 to 0.00)-0.05 (-0.08 to -0.02)-0.03 (-0.06 to 0.00)
Cycle 12 Day 1-0.05 (-0.08 to -0.02)-0.04 (-0.07 to -0.01)-0.04 (-0.06 to -0.01)-0.04 (-0.07 to -0.01)-0.06 (-0.09 to -0.03)-0.03 (-0.06 to 0.00)
Cycle 14 Day 1-0.04 (-0.08 to 0.00)-0.04 (-0.07 to -0.00)-0.03 (-0.06 to -0.00)-0.04 (-0.07 to -0.01)-0.04 (-0.08 to -0.00)-0.02 (-0.06 to 0.02)
Cycle 16 Day 1-0.09 (-0.13 to -0.05)-0.00 (-0.04 to 0.04)-0.03 (-0.07 to 0.01)-0.03 (-0.06 to 0.01)-0.07 (-0.13 to 0.00)-0.06 (-0.10 to -0.01)
Cycle 18 Day 1-0.01 (-0.06 to 0.05)-0.05 (-0.09 to 0.00)-0.04 (-0.08 to 0.00)-0.07 (-0.10 to -0.03)-0.19 (-0.29 to -0.09)-0.01 (-0.05 to 0.04)
Cycle 20 Day 1-0.03 (-0.10 to 0.04)-0.01 (-0.06 to 0.04)-0.03 (-0.08 to 0.02)-0.10 (-0.15 to -0.06)—-0.03 (-0.08 to 0.02)
Cycle 22 Day 10.04 (-0.03 to 0.11)-0.01 (-0.07 to 0.05)-0.06 (-0.11 to 0.00)-0.05 (-0.11 to 0.00)—-0.08 (-0.14 to -0.03)
Cycle 24 Day 10.08 (-0.01 to 0.18)——-0.06 (-0.15 to 0.04)——
End of treatment-0.07 (-0.13 to -0.02)-0.03 (-0.10 to 0.03)-0.02 (-0.06 to 0.02)-0.03 (-0.06 to 0.01)-0.09 (-0.14 to -0.05)-0.06 (-0.11 to -0.01)
SecondaryChange From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)

The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: "Is the previous card the same?". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press "Yes", and if not press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

Time frame:
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)
Units on a scaleEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Cycle 2 Day 10.01 (-0.02 to 0.05)0.02 (-0.01 to 0.05)0.02 (0.00 to 0.05)0.01 (-0.01 to 0.04)0.02 (-0.01 to 0.05)0.01 (-0.02 to 0.04)
Cycle 3 Day 10.06 (0.02 to 0.09)0.01 (-0.02 to 0.05)0.01 (-0.01 to 0.04)0.01 (-0.02 to 0.03)-0.01 (-0.04 to 0.02)-0.00 (-0.04 to 0.03)
Cycle 4 Day 10.04 (0.01 to 0.08)0.03 (-0.00 to 0.06)0.02 (-0.01 to 0.04)-0.01 (-0.04 to 0.01)-0.02 (-0.05 to 0.01)-0.01 (-0.05 to 0.02)
Cycle 5 Day 10.02 (-0.01 to 0.06)0.03 (-0.00 to 0.07)0.03 (0.00 to 0.05)-0.01 (-0.04 to 0.02)-0.02 (-0.05 to 0.01)0.02 (-0.01 to 0.05)
Cycle 6 Day 10.03 (-0.01 to 0.06)0.03 (-0.00 to 0.07)0.03 (0.01 to 0.06)0.01 (-0.02 to 0.04)-0.00 (-0.03 to 0.03)0.01 (-0.03 to 0.04)
Cycle 8 Day 10.03 (-0.01 to 0.06)0.02 (-0.02 to 0.06)0.03 (0.00 to 0.05)0.01 (-0.02 to 0.03)-0.01 (-0.04 to 0.02)0.01 (-0.02 to 0.05)
Cycle 10 Day 10.07 (0.03 to 0.11)0.03 (-0.00 to 0.07)0.03 (0.00 to 0.05)0.02 (-0.01 to 0.05)-0.01 (-0.05 to 0.02)0.01 (-0.02 to 0.05)
Cycle 12 Day 10.05 (0.01 to 0.08)0.01 (-0.03 to 0.05)0.02 (-0.01 to 0.05)0.01 (-0.02 to 0.04)-0.00 (-0.04 to 0.03)0.03 (-0.01 to 0.07)
Cycle 14 Day 10.00 (-0.05 to 0.05)0.03 (-0.01 to 0.07)0.03 (-0.01 to 0.07)-0.00 (-0.04 to 0.03)0.01 (-0.04 to 0.06)0.02 (-0.03 to 0.07)
Cycle 16 Day 10.03 (-0.03 to 0.08)0.05 (-0.01 to 0.10)0.05 (0.00 to 0.09)-0.02 (-0.05 to 0.02)-0.01 (-0.10 to 0.08)0.03 (-0.03 to 0.08)
Cycle 18 Day 10.02 (-0.06 to 0.09)0.01 (-0.04 to 0.07)0.06 (0.02 to 0.11)-0.02 (-0.06 to 0.03)-0.18 (-0.30 to -0.06)0.05 (-0.01 to 0.10)
Cycle 20 Day 1-0.06 (-0.15 to 0.03)0.07 (0.00 to 0.13)0.02 (-0.05 to 0.08)-0.01 (-0.06 to 0.05)—0.02 (-0.04 to 0.09)
Cycle 22 Day 10.02 (-0.07 to 0.11)0.05 (-0.02 to 0.12)0.04 (-0.03 to 0.11)-0.07 (-0.14 to 0.00)—0.03 (-0.04 to 0.11)
Cycle 24 Day 10.09 (-0.03 to 0.21)——0.01 (-0.11 to 0.13)——
End of treatment-0.03 (-0.10 to 0.05)0.03 (-0.05 to 0.11)0.03 (-0.02 to 0.07)0.01 (-0.04 to 0.05)-0.03 (-0.08 to 0.02)0.02 (-0.05 to 0.08)
SecondaryChange From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)

The International Shopping List task is a measure of verbal learning and uses a well validated list learning paradigm administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to the participant at the rate of one word every 2 seconds. Once all 12 words had been read, the participant was asked to recall as many of the words as quickly as possible. The words recalled by the participant were marked on the computer screen. When the participant could recall no more words, the same list was read again. The words recalled by the participant were recorded. This was then repeated a third time. Total number of correct responses on 3 consecutive trials at a single assessment was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

Time frame:
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)
Units on a scaleEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Cycle 2 Day 1-0.02 (-1.89 to 1.84)-1.13 (-2.90 to 0.64)0.25 (-1.01 to 1.52)-0.45 (-1.76 to 0.86)0.96 (-0.50 to 2.43)0.16 (-1.51 to 1.83)
Cycle 3 Day 10.19 (-1.66 to 2.03)-0.81 (-2.58 to 0.96)0.14 (-1.15 to 1.43)-1.04 (-2.36 to 0.29)-0.08 (-1.59 to 1.44)-0.56 (-2.21 to 1.09)
Cycle 4 Day 10.58 (-1.26 to 2.42)0.26 (-1.54 to 2.05)0.28 (-1.05 to 1.61)0.24 (-1.12 to 1.60)1.30 (-0.26 to 2.86)-0.87 (-2.59 to 0.84)
Cycle 5 Day 11.30 (-0.51 to 3.12)-0.66 (-2.53 to 1.21)0.59 (-0.77 to 1.95)-0.94 (-2.33 to 0.45)1.23 (-0.36 to 2.82)0.74 (-0.97 to 2.45)
Cycle 6 Day 10.18 (-1.64 to 1.99)0.81 (-1.06 to 2.68)0.50 (-0.87 to 1.87)0.08 (-1.31 to 1.47)0.82 (-0.83 to 2.46)-0.51 (-2.31 to 1.29)
Cycle 8 Day 10.84 (-1.00 to 2.68)0.60 (-1.30 to 2.50)1.69 (0.29 to 3.08)0.15 (-1.27 to 1.57)0.44 (-1.23 to 2.11)1.70 (-0.11 to 3.50)
Cycle 10 Day 10.26 (-1.68 to 2.21)2.59 (0.65 to 4.52)0.86 (-0.56 to 2.27)0.13 (-1.46 to 1.72)2.29 (0.53 to 4.05)0.97 (-0.99 to 2.93)
Cycle 12 Day 12.87 (0.86 to 4.88)0.02 (-2.06 to 2.10)0.11 (-1.52 to 1.73)0.69 (-0.98 to 2.35)1.74 (-0.25 to 3.72)3.10 (1.06 to 5.14)
Cycle 14 Day 11.91 (-0.71 to 4.53)1.46 (-0.85 to 3.78)2.27 (0.36 to 4.17)0.94 (-0.86 to 2.73)-4.43 (-7.11 to -1.75)2.67 (0.09 to 5.25)
Cycle 16 Day 14.52 (1.58 to 7.46)0.87 (-2.06 to 3.79)1.36 (-1.11 to 3.84)1.04 (-0.99 to 3.07)3.46 (-1.26 to 8.18)1.97 (-0.93 to 4.87)
Cycle 18 Day 14.77 (0.82 to 8.73)0.66 (-2.50 to 3.81)-0.27 (-2.89 to 2.36)-0.52 (-2.77 to 1.73)-0.35 (-6.90 to 6.21)3.13 (0.00 to 6.27)
Cycle 20 Day 1-2.72 (-7.47 to 2.03)-1.44 (-4.91 to 2.03)0.56 (-2.81 to 3.92)1.20 (-1.84 to 4.24)—0.56 (-2.89 to 4.01)
Cycle 22 Day 1-5.72 (-10.47 to -0.97)-0.28 (-4.22 to 3.66)2.17 (-1.68 to 6.01)-0.36 (-4.21 to 3.48)—3.99 (0.07 to 7.91)
Cycle 24 Day 1-8.49 (-15.06 to -1.92)——-3.35 (-9.86 to 3.16)——
End of treatment1.02 (-2.99 to 5.04)-1.62 (-5.95 to 2.71)0.80 (-1.80 to 3.40)-0.27 (-2.47 to 1.92)2.37 (-0.54 to 5.27)-0.60 (-4.09 to 2.89)
SecondaryChange From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)

This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.

Time frame:
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)
Units on a scaleEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)
Cycle 2 Day 10.10 (-0.85 to 1.06)-0.84 (-1.76 to 0.08)-0.12 (-0.77 to 0.53)-0.59 (-1.28 to 0.09)-0.22 (-0.96 to 0.53)-0.25 (-1.11 to 0.62)
Cycle 3 Day 1-0.33 (-1.28 to 0.62)-1.32 (-2.24 to -0.40)-0.14 (-0.81 to 0.52)-0.77 (-1.46 to -0.07)-0.87 (-1.64 to -0.10)-0.30 (-1.15 to 0.56)
Cycle 4 Day 1-0.44 (-1.38 to 0.50)-0.91 (-1.86 to 0.03)0.03 (-0.66 to 0.72)-0.25 (-0.97 to 0.47)-0.02 (-0.82 to 0.78)-1.06 (-1.95 to -0.18)
Cycle 5 Day 1-0.35 (-1.29 to 0.59)-0.57 (-1.54 to 0.40)0.02 (-0.69 to 0.73)-0.46 (-1.20 to 0.27)0.09 (-0.74 to 0.92)0.17 (-0.72 to 1.05)
Cycle 6 Day 10.48 (-0.46 to 1.42)-0.38 (-1.35 to 0.59)0.12 (-0.59 to 0.84)-0.22 (-0.95 to 0.52)0.30 (-0.55 to 1.15)-0.28 (-1.21 to 0.66)
Cycle 8 Day 10.56 (-0.38 to 1.50)-0.24 (-1.23 to 0.75)0.02 (-0.70 to 0.74)-0.49 (-1.24 to 0.25)-1.08 (-1.94 to -0.22)-0.16 (-1.10 to 0.77)
Cycle 10 Day 10.29 (-0.74 to 1.31)0.80 (-0.22 to 1.82)0.54 (-0.20 to 1.28)0.23 (-0.61 to 1.08)0.25 (-0.67 to 1.16)-0.00 (-1.02 to 1.02)
Cycle 12 Day 10.90 (-0.15 to 1.95)0.13 (-0.95 to 1.21)0.22 (-0.63 to 1.07)0.19 (-0.70 to 1.07)0.60 (-0.43 to 1.64)0.42 (-0.64 to 1.49)
Cycle 14 Day 10.38 (-0.99 to 1.75)0.06 (-1.15 to 1.27)1.06 (0.06 to 2.06)0.11 (-0.85 to 1.07)-1.80 (-3.31 to -0.30)0.35 (-1.00 to 1.71)
Cycle 16 Day 10.89 (-0.66 to 2.43)0.52 (-1.02 to 2.05)0.68 (-0.62 to 1.98)-0.12 (-1.22 to 0.98)0.40 (-2.09 to 2.88)-0.22 (-1.75 to 1.30)
Cycle 18 Day 11.06 (-1.02 to 3.14)0.68 (-0.98 to 2.34)0.38 (-1.00 to 1.76)-0.24 (-1.54 to 1.07)-0.39 (-3.85 to 3.07)-0.33 (-1.97 to 1.32)
Cycle 20 Day 1-1.22 (-3.73 to 1.28)0.16 (-1.67 to 1.98)-0.24 (-2.01 to 1.53)-0.18 (-1.78 to 1.43)—-0.70 (-2.52 to 1.11)
Cycle 22 Day 1-3.22 (-5.73 to -0.72)0.68 (-1.40 to 2.76)0.80 (-1.23 to 2.83)-0.64 (-2.67 to 1.39)—0.37 (-1.70 to 2.43)
Cycle 24 Day 1-2.43 (-5.89 to 1.04)——-0.80 (-4.25 to 2.64)——
End of treatment-0.87 (-2.99 to 1.24)-2.31 (-4.58 to -0.04)0.52 (-0.84 to 1.89)-0.85 (-2.06 to 0.35)-0.19 (-1.71 to 1.34)0.11 (-1.72 to 1.95)
SecondaryNumber of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy)

PR Interval was determined by ECG measurement. PR interval had following categories: change from baseline\>=25 percent, 40 to \<60 milliseconds (msec), 60 to \<80 msec and \>=80 msec. Baseline was defined as the average of the triplicate measurements prior to the first dose of study drug.

Time frame:
From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Count of participants · Participants
Number of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy)
ParticipantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Substudy
Change from baseline: >25%43896102
Absolute value: 40-<60 msec3222372
Absolute value: 60-<80 msec0124110
Absolute value: >=80 msec1001120
Other pre-specifiedPercentage of Participants With Overall and Intracranial Objective Response (Phase 2 and DDI Sub-study)

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 milliliter (mm) on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \<10 mm. PR was defined as a 30 percent (%) or more decrease in sum of lesion dimensions (SLD) of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.

Time frame:
From first dose of study treatment to end of treatment maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall and Intracranial Objective Response (Phase 2 and DDI Sub-study)
Percentage of participantsEXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)Phase 2DDI Sub-study
Objective response90.0 (73.5 to 97.9)77.8 (57.7 to 91.4)56.7 (43.2 to 69.4)40.0 (28.0 to 52.9)37.0 (23.2 to 52.5)38.3 (24.5 to 53.6)40.6 (23.7 to 59.4)
Intracranial objective response75.0 (34.9 to 96.8)58.8 (32.9 to 81.6)66.7 (48.2 to 82.0)53.3 (37.9 to 68.3)43.2 (27.1 to 60.5)56.0 (34.9 to 75.6)25.0 (7.3 to 52.4)

Adverse events

Collected over From first dose of study treatment to end of treatment (maximum of 96.58 months of treatment exposure for Phase 1, maximum of 89.65 months of treatment exposure for Phase 2 and maximum of 68.69 months of treatment exposure for DDI participants). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg QD (Phase 1)3/3 (100%)3/3 (100%)3/3 (100%)
25 mg QD (Phase 1)2/3 (66.7%)2/3 (66.7%)3/3 (100%)
50 mg QD (Phase 1)3/3 (100%)1/3 (33.3%)3/3 (100%)
75 mg QD (Phase 1)6/12 (50%)6/12 (50%)12/12 (100%)
100 mg QD (Phase 1)9/17 (52.9%)10/17 (58.8%)17/17 (100%)
150 mg QD (Phase 1)3/3 (100%)3/3 (100%)3/3 (100%)
200 mg QD (Phase 1)2/3 (66.7%)2/3 (66.7%)3/3 (100%)
35 mg BID (Phase 1)3/3 (100%)2/3 (66.7%)3/3 (100%)
75 mg BID (Phase 1)2/3 (66.7%)2/3 (66.7%)3/3 (100%)
100 mg BID (Phase 1)2/4 (50%)2/4 (50%)4/4 (100%)
Japan Lead-In Cohort (LIC)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
EXP-1 (Phase 2)8/30 (26.7%)15/30 (50%)30/30 (100%)
EXP-2 (Phase 2)13/27 (48.1%)11/27 (40.7%)27/27 (100%)
EXP-3 (Phase 2)25/60 (41.7%)34/60 (56.7%)59/60 (98.3%)
EXP-4 (Phase 2)46/65 (70.8%)31/65 (47.7%)65/65 (100%)
EXP-5 (Phase 2)37/46 (80.4%)23/46 (50%)45/46 (97.8%)
EXP-6 (Phase 2)22/47 (46.8%)21/47 (44.7%)47/47 (100%)
DDI Substudy17/32 (53.1%)13/32 (40.6%)32/32 (100%)
Most frequent serious events
Showing 10 of 177
Most frequent serious events
Event10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)Japan Lead-In Cohort (LIC)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Substudy
PneumoniaInfections and infestations0/30/30/30/122/172/30/30/30/30/40/34/304/273/605/652/461/471/32
Cardiac arrestCardiac disorders0/30/30/30/120/170/30/31/30/30/40/30/300/270/600/650/461/470/32
Pericardial effusionCardiac disorders0/30/30/30/120/170/31/31/30/30/40/31/300/270/601/652/461/470/32
Abdominal painGastrointestinal disorders0/30/30/31/120/170/30/30/31/30/40/30/300/270/600/650/460/470/32
Disease progressionGeneral disorders1/31/30/31/124/171/30/30/31/30/40/32/300/277/608/656/466/475/32
CellulitisInfections and infestations0/30/30/30/120/170/31/30/30/30/40/32/301/270/600/650/460/470/32
PyelonephritisInfections and infestations0/30/30/30/120/170/31/30/30/30/40/30/300/270/600/650/460/470/32
Respiratory tract infectionInfections and infestations0/30/30/30/120/170/31/30/30/30/40/32/301/270/600/650/461/470/32
Urinary tract infectionInfections and infestations0/30/30/30/121/170/31/30/30/30/40/31/301/271/601/650/460/470/32
FallInjury, poisoning and procedural complications0/30/30/30/120/170/31/30/30/30/40/21/300/270/605/650/460/471/32
Most frequent other events
Showing 10 of 367
Most frequent other events
Event10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)Japan Lead-In Cohort (LIC)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)DDI Substudy
AnaemiaBlood and lymphatic system disorders0/30/30/33/127/173/31/31/32/32/40/36/302/276/6018/657/467/478/32
Oedema peripheralGeneral disorders3/31/31/34/1210/173/31/30/32/33/41/313/3015/2733/6025/6516/4625/4714/32
Alanine aminotransferase increasedInvestigations0/30/30/33/124/170/30/30/30/31/42/36/302/2712/607/658/467/71/32
Blood cholesterol increasedInvestigations0/30/30/36/124/171/30/30/30/31/43/311/3013/2719/6019/6516/4619/4717/32
HypercholesterolaemiaMetabolism and nutrition disorders1/32/31/37/1212/172/33/31/31/31/40/316/3014/2733/6038/6527/4625/4715/32
HypertriglyceridaemiaMetabolism and nutrition disorders0/31/31/35/127/171/32/30/31/31/43/323/3016/2737/6045/6532/4625/4723/32
HypomagnesaemiaMetabolism and nutrition disorders0/31/31/30/120/173/30/31/30/30/40/32/301/273/602/655/464/470/32
DyspnoeaRespiratory, thoracic and mediastinal disorders1/31/31/33/124/170/30/33/31/32/41/38/306/2722/6018/6511/4617/4710/32
DiarrhoeaGastrointestinal disorders0/30/31/33/124/171/32/30/30/33/40/311/306/2712/6022/659/469/475/32
NauseaGastrointestinal disorders1/31/30/33/124/170/31/30/31/33/41/36/307/279/6018/6510/469/473/32

Baseline characteristics

The safety analysis set included all enrolled patients who receive at least one dose of PF-06463922 (including Lead-in dose).

Age, Customized
Age, Customized(Participants)10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)Japan Lead-In Cohort (LIC)Drug-drug Interaction (DDI) Sub-studyTotal
<18 years0000000000000000000
18-44 years010571100245141913122591
45-64 years1136912221181334372627120204
>=65 years210111011189129780769
Sex: Female, Male
Sex: Female, Male(Participants)10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)Japan Lead-In Cohort (LIC)Drug-drug Interaction (DDI) Sub-studyTotal
Female20171122232131738372527215206
Male1325611102171022282120117158
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)10 mg QD (Phase 1)25 mg QD (Phase 1)50 mg QD (Phase 1)75 mg QD (Phase 1)100 mg QD (Phase 1)150 mg QD (Phase 1)200 mg QD (Phase 1)35 mg BID (Phase 1)75 mg BID (Phase 1)100 mg BID (Phase 1)EXP-1 (Phase 2)EXP-2 (Phase 2)EXP-3 (Phase 2)EXP-4 (Phase 2)EXP-5 (Phase 2)EXP-6 (Phase 2)Japan Lead-In Cohort (LIC)Drug-drug Interaction (DDI) Sub-studyTotal
WHITE22371322123101325322725021190
BLACK1000010100101001006
ASIAN0103201000171023231416311124
Others00001000001213230013
Unspecified000210011112107320031
08

Study locations

77 sites
  • Highlands Oncology Group/Research
    Fayetteville, Arkansas 72703, United States
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
  • Chao Family Comprehensive Cancer Center
    Orange, California 92868-3201, United States
  • UC Irvine Medical Center
    Orange, California 92868-3201, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Anschutz Outpatient Pavillion (AOP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • MDZ: Yale-New Haven Hospital
    New Haven, Connecticut 06504, United States
  • Smilow Cancer Hospital at Yale-New Haven
    New Haven, Connecticut 06510, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Karmanos Center Institute
    Detroit, Michigan 48201, United States
  • Karmanos Cancer Institute
    Farmington Hills, Michigan 48334, United States
  • Siteman Cancer Center-West County
    Creve Coeur, Missouri 63141, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Siteman Cancer Center-South County
    Saint Louis, Missouri 63129, United States
  • Rockefeller Patient Pavilion - Memorial Sloan Kettering
    New York, New York 10022, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Rochester Regional Health System
    Rochester, New York 14621, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • The Ohio State University
    Columbus, Ohio 43205, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • The Ohio State University
    Columbus, Ohio 43221, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Sarah Cannon Research Institute (Pharmacy)
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Chris O'Brien Lifehouse
    Sydney Local Health District [rpa], New South Wales 2050, Australia
  • Chris O'Brien Lifehouse
    Sydney, New South Wales 2050, Australia
  • Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • University Hospital Antwerp
    Edegem, 2650, Belgium
  • British Columbia Cancer Agency-Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • CHU Grenoble/ Hôpital Albert Michallon
    Grenoble Cedex 9, 38043, France
  • CHU de Rennes - Hôpital Pontchaillou - CIC Inserm
    Rennes Cedex 9, 35033, France
  • CHU de Rennes - Hôpital Pontchaillou
    Rennes Cedex 9, 35033, France
  • Institut Universitaire du Cancer de Toulouse (IUCT-O)
    Toulouse Cedex 9, 31059, France
  • Institut Gustave Roussy (comite poumon-pneumologie)
    Villejuif Cedex, 94805, France
  • Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques
    Villejuif, 94805, France
  • Universitaetsklinik Koeln
    Cologne, 50937, Germany
  • Department of Clinical Oncology, Prince of Wales Hospital
    Shatin, Hong Kong
  • Struttura Operativa Complessa Oncologia
    Aviano (PN), 33081, Italy
  • Dipartimento di Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative
    Milano, 20132, Italy
  • Unita di Farmacologia Clinica e Nuovi Farmaci
    Milano, 20141, Italy
  • Oncologia Medica
    Perugia, 06132, Italy
  • Aichi Cancer Center Hospital
    Nagoya, Aichi 464-8681, Japan
  • Nagoya University Hospital
    Nagoya, Aichi 466-8560, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Hyogo Cancer Center
    Akashi, Hyogo 673-8558, Japan
  • Kindai University Hospital
    Osakasayama, Osaka 589-8511, Japan
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 411-8777, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • The Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo, 135-8550, Japan
  • Seoul National University Hospital / Department of Internal Medicine
    Seoul, 03080, Korea, Republic of
  • National University Hospital
    Singapore, 119074, Singapore
  • National University Hospital Medical Centre
    Singapore, 119082, Singapore
  • National Cancer Center
    Singapore, 168583, Singapore
  • National Cancer Center
    Singapore, 169610, Singapore
  • Hospital Universitario Quiron Madrid
    Pozuelo de Alarcón, Madrid 28223, Spain
  • Clinica Universidad De Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Quiron Dexeus
    Barcelona, 08028, Spain
  • Hospital Universitari de la Vall D'Hebron Edificio General. Planta Baja. UITM. Servicio de Oncologia
    Barcelona, 08035, Spain
  • Hospital of Lausanne (CHUV)
    Lausanne, 1011, Switzerland
  • Kantonsspital Winterthur
    Winterthur, 8401, Switzerland
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Soo RA, Huat Tan E, Hayashi H, Seto T, Lin CC, Ou SI, Kim DW, Liu G, Abbattista A, Martini JF, Hooi Wong C, Toffalorio F, Solomon BJ. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer. 2022 Jul;169:67-76. doi: 10.1016/j.lungcan.2022.05.012. Epub 2022 May 23. PubMed 35660971 ↗
  • Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. J Thorac Oncol. 2022 Apr;17(4):568-577. doi: 10.1016/j.jtho.2021.12.011. Epub 2022 Jan 10. PubMed 35026476 ↗
  • Chen J, Ruiz-Garcia A, James LP, Peltz G, Thurm H, Clancy J, Hibma J. Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer. Clin Pharmacol Ther. 2021 Nov;110(5):1273-1281. doi: 10.1002/cpt.2228. Epub 2021 Jun 26. PubMed 33973232 ↗
  • Chen J, O'Gorman MT, James LP, Klamerus KJ, Mugundu G, Pithavala YK. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study. Clin Pharmacokinet. 2021 Oct;60(10):1313-1324. doi: 10.1007/s40262-021-01015-z. Epub 2021 May 3. PubMed 33937954 ↗
  • Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer. 2020 Jun;144:10-19. doi: 10.1016/j.lungcan.2020.02.011. Epub 2020 Mar 10. PubMed 32344248 ↗
  • Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol. 2020 Feb;15(1):55-65. doi: 10.1007/s11523-020-00702-4. PubMed 32060867 ↗
  • Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. PubMed 31669155 ↗
  • Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum In: Lancet Oncol. 2019 Jan;20(1):e10. doi: 10.1016/S1470-2045(18)30927-6. PubMed 30413378 ↗
  • Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. PubMed 29074098 ↗
  • Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23. PubMed 26698910 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Mar 2017, 38 months.

Results were first posted in May 2018, 1 year 2 months after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 38 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2013
First posted
Oct 28, 2013
StartActual
Jan 8, 2014
Primary completionActual
Mar 15, 2017
CompletionActual
May 24, 2023
Results first posted
May 29, 2018
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01970865
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 28, 2013
Start date
Jan 8, 2014
Primary completion
Mar 15, 2017
Completion
May 24, 2023
Results posted
May 29, 2018
Last update
Aug 12, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion